Rapport Therapeutics Advances Bipolar Mania Treatment After Successful Clinical Trial

Boston, Friday, 23 October 2026.
Rapport Therapeutics reported positive Phase 2 trial results for lead drug RAP-219, demonstrating significant symptom reduction in bipolar mania patients without common severe side effects, opening a multi-billion-dollar market opportunity.